Pharvaris BV, a prominent player in the Biotechnology industry, has been making waves in the NASDAQ exchange with its stock surging over 6% despite overall market gains. This impressive performance is backed by a strong buy consensus from analysts, with three strong buys and two buys against a single sell.
The stock's robust performance is reflected in its valuation hype value of 17.95, significantly higher than its market value of 18.04. This indicates a strong investor sentiment and a potential for further growth. The company's accumulation distribution stands at 11.8K, suggesting a healthy level of stock accumulation.
Analysts have set a target price estimated value of 24.15 for Pharvaris BV, with the highest estimated target price reaching 26.81. This presents a possible upside price of 25.51, a promising prospect for investors. On the flip side, the possible downside price is pegged at 16.22, indicating a balanced risk-reward scenario.
Despite the daily balance of power indicating a loss of 0.76, the rate of daily change stands at 0.93, suggesting a positive momentum. The company's fiscal year ends in December, providing ample time for the stock to reach the naive expected forecast value of 20.87.
In conclusion, Pharvaris BV's stock performance is outperforming market expectations, making it a potential investment opportunity. However, investors are advised to keep an eye on the market trends and make informed decisions. Recent volatility spikes have left many private investors puzzled. In this context, we examine Pharvaris BV, currently trading at $18.04. Recent price movements suggest a potential rebound in July. Pharvaris BV has a historical hype elasticity of -0.09, compared to the competition's average of -0.01. The company's value is expected to decline following the next press release, with a predicted price drop to $17.95. The substantial volatility of headline impact on the stock price makes predictions based on news or social media less reliable. The next news is projected to decrease the price by -0.5%, while the current daily expected return is -0.16%. With a 90-day investment horizon, the next anticipated announcement is expected in approximately 6 days.
The successful prediction of Pharvaris
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Pharvaris BV, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Pharvaris based on Pharvaris hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Pharvaris's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Pharvaris's related companies.
Use Technical Analysis to project Pharvaris expected Price
Pharvaris technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Pharvaris technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Pharvaris trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Pharvaris Gross Profit
Pharvaris Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Pharvaris previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Pharvaris Gross Profit growth over the last 10 years. Please check Pharvaris'
gross profit and other
fundamental indicators for more details.
Another angle On Pharvaris
Net Loss for the year was (98.81
M) with profit before overhead, payroll, taxes, and interest of 0.
| 2021 | 2022 | 2023 | 2024 (projected) |
Other Current Liab | 4.8M | 12.1M | 11.1M | 11.6M | Total Assets | 212.1M | 167.7M | 399.0M | 419.0M |
Current Deferred Revenue Breakdown
Pharvaris Current Deferred Revenue yearly trend continues to be comparatively stable with very little volatility. Current Deferred Revenue will likely drop to about 344.2
K in 2024. Current Deferred Revenue usually refers to revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. At this time, Pharvaris' Current Deferred Revenue is comparatively stable compared to the past year.
| 2010 | 430,278 |
| 2023 | 387,250 |
| 2024 | 344,222 |
As Benjamin Graham once said, the stock market is a voting machine in the short term, but a weighing machine in the long term. Pharvaris BV is a testament to this, with its stock surging over 6% despite market gains. The company's robust financial health, reflected in a high current ratio of 12.85X and substantial working capital of $383.25M, provides a solid foundation for this performance. However, investors should be aware of the company's high probability of bankruptcy at 71.90% and negative return on assets of 0.25. Despite these risks, the strong institutional ownership of 85.80% suggests confidence in Pharvaris BV's long-term prospects.
Pharvaris newest price drop is misleading
Despite Pharvaris BV's recent Treynor ratio drop to -0.31, it's not a definitive sign of future price depreciation. This risk-adjusted return measure can occasionally dip negative due to short-term market fluctuations or company-specific events, but it doesn't necessarily forecast future price trends. Investors should consider a wider range of financial indicators and market factors before trading. Pharvaris BV has very low volatility, with skewness of 0.1 and kurtosis of 1.65. Understanding market volatility trends can help investors time the market. Proper use of volatility indicators allows traders to gauge Pharvaris' stock risk against market volatility in both bullish and bearish trends.
The increased volatility of bear markets can directly affect Pharvaris' stock price and stress investors as they see their shares' value drop, often prompting portfolio rebalancing with different financial instruments.In conclusion, Pharvaris BV stock presents a compelling investment opportunity despite the recent reset. The company's valuation real value stands at
$20.08, which is higher than the current market value of
$18.04. This indicates a potential undervaluation of the stock. Moreover, the analyst overall consensus is a 'Strong Buy', with 3 strong buys and 2 buys against a single sell. The analyst target price estimated value is $24.15, suggesting a possible upside price of $25.51. However, investors should also consider the possible downside price of $16.22. Given these factors, Pharvaris BV stock could be a valuable addition to a diversified portfolio..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Pharvaris BV. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]